| Year |
Citation |
Score |
| 2024 |
Sánchez D, Cesarman-Maus G, Romero L, Sánchez-Verin R, Vail D, Guadarrama M, Pelayo R, Sarmiento-Silva RE, Lizano M. The NDV-MLS as an Immunotherapeutic Strategy for Breast Cancer: Proof of Concept in Female Companion Dogs with Spontaneous Mammary Cancer. Viruses. 16. PMID 38543739 DOI: 10.3390/v16030372 |
0.754 |
|
| 2023 |
Moirano S, Turek M, Sanchez D, Vail D, Van Asselt N, Lawrence J, Forrest L. Intensity-modulated radiotherapy and chemotherapy for canine right atrial tumors: A retrospective study of seven dogs. Veterinary Radiology & Ultrasound : the Official Journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association. PMID 37800663 DOI: 10.1111/vru.13303 |
0.73 |
|
| 2021 |
Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, Sriramaneni RN, Jin WJ, Massey C, Rakhmilevich AL, Vail D, et al. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Science Translational Medicine. 13. PMID 34261797 DOI: 10.1126/scitranslmed.abb3631 |
0.73 |
|
| 2020 |
Stevens A, Turek M, Vail D, Christensen N, Forrest L. Definitive-intent intensity modulated radiotherapy for modified-Adams' stage 4 canine sinonasal cancer: A retrospective study of 29 cases (2011-2017). Veterinary Radiology & Ultrasound : the Official Journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association. PMID 32713101 DOI: 10.1111/vru.12899 |
0.736 |
|
| 2016 |
Saba C, Paoloni M, Mazcko C, Kisseberth W, Burton JH, Smith A, Wilson-Robles H, Allstadt S, Vail D, Henry C, Lana S, Ehrhart EJ, Charles B, Kent M, Lawrence J, et al. A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model. Plos One. 11: e0149194. PMID 26866698 DOI: 10.1371/journal.pone.0149194 |
0.754 |
|
| 2015 |
Khanna C, Vail D, Rosenberg M. Letter to Editor. Journal of Veterinary Internal Medicine / American College of Veterinary Internal Medicine. PMID 26617055 DOI: 10.1111/jvim.13790 |
0.671 |
|
| 2015 |
Paoloni M, Mazcko C, Selting K, Lana S, Barber L, Phillips J, Skorupski K, Vail D, Wilson H, Biller B, Avery A, Kiupel M, LeBlanc A, Bernhardt A, Brunkhorst B, et al. Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma. Plos One. 10: e0129954. PMID 26091536 DOI: 10.1371/journal.pone.0129954 |
0.714 |
|
| 2014 |
Paoloni M, Webb C, Mazcko C, Cherba D, Hendricks W, Lana S, Ehrhart EJ, Charles B, Fehling H, Kumar L, Vail D, Henson M, Childress M, Kitchell B, Kingsley C, et al. Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials. Plos One. 9: e90028. PMID 24637659 DOI: 10.1371/Journal.Pone.0090028 |
0.763 |
|
| 2012 |
Vail DD. Toxic fables: the advertising and marketing of agricultural chemicals in the great plains, 1945-1985. Endeavour. 36: 165-73. PMID 23177323 DOI: 10.1016/J.Endeavour.2012.09.007 |
0.693 |
|
| 2009 |
Khanna C, London C, Vail D, Mazcko C, Hirschfeld S. Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5671-7. PMID 19737961 DOI: 10.1158/1078-0432.CCR-09-0719 |
0.741 |
|
| 2009 |
Vail D, Hellmén E. International Veterinary Cancer Meetings 2003. Veterinary and Comparative Oncology. 1: 169-70. PMID 19379177 DOI: 10.1111/j.1476-5810.2003.00034.x |
0.745 |
|
| 2009 |
Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, et al. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. Plos One. 4: e4972. PMID 19330034 DOI: 10.1371/Journal.Pone.0004972 |
0.75 |
|
| 2008 |
Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, Birkus G, Cihlar T, Wu S, Li B, Liu X, Henne IN, Wolfgang GH, Desai M, Rhodes GR, ... ... Vail D, et al. GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2824-32. PMID 18451250 DOI: 10.1158/1078-0432.Ccr-07-2061 |
0.705 |
|
| 2008 |
Lawrence J, Forrest L, Adams W, Vail D, Thamm D. Four-fraction radiation therapy for macroscopic soft tissue sarcomas in 16 dogs. Journal of the American Animal Hospital Association. 44: 100-8. PMID 18451067 DOI: 10.5326/0440100 |
0.707 |
|
| 2006 |
Rusk A, Cozzi E, Stebbins M, Vail D, Graham J, Valli V, Henkin J, Sharpee R, Khanna C. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7456-64. PMID 17189419 DOI: 10.1158/1078-0432.CCR-06-0110 |
0.746 |
|
| 2006 |
Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S, Withrow S. The dog as a cancer model. Nature Biotechnology. 24: 1065-6. PMID 16964204 DOI: 10.1038/Nbt0906-1065B |
0.75 |
|
| Show low-probability matches. |
